

February 6, 2018

# CymaBay Therapeutics to Participate in Investor Conferences in February

NEWARK, Calif., Feb. 06, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in upcoming investor conferences, including the SunTrust Robinson Humphrey 4<sup>th</sup> Annual Orphan Drug Day and the LEERINK Partners 7<sup>th</sup> Annual Global Healthcare Conference.

## ***SunTrust Robinson Humphrey 4<sup>th</sup> Annual Orphan Drug Day***

Date: Tuesday, February 13  
Format: One-on-One Format  
Location: JW Marriott Essex House, New York City

## ***LEERINK Partners 7<sup>th</sup> Annual Global Healthcare Conference***

Date: Wednesday, February 14  
Time: 11:00am Eastern Time  
Location: Lotte New York Palace Hotel, New York City  
Webcast: <http://ir.cymabay.com/events>

## **About CymaBay**

CymaBay Therapeutics, Inc. ([CBAY](http://www.cbay.com)) is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPAR $\delta$  agonist currently in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Two Phase 2 studies of seladelpar established proof of concept in PBC. CymaBay is currently planning to advance development of seladelpar into Phase 3 for PBC and Phase 2 for NASH. Arhalofenate is a potential urate-lowering anti-flare therapy that has been found to reduce painful flares in joints while at the same time lowering serum uric acid by promoting excretion of uric acid by the kidney. This dual action addresses both the signs and symptoms of gout while managing the underlying pathophysiology of hyperuricemia. Arhalofenate has been licensed in the U.S. to Kowa Pharmaceuticals America, Inc. CymaBay retains full development and commercialization rights for arhalofenate outside the U.S.

For additional information about CymaBay visit [www.cymabay.com](http://www.cymabay.com).

## **Contact:**

Hans Vitzthum  
LifeSci Advisors, LLC  
212-915-2568  
[Hans@LifeSciAdvisors.com](mailto:Hans@LifeSciAdvisors.com)



Source: CymaBay Therapeutics, Inc.